Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD

Abstract Background Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a particular amyloid form that is highly synaptotoxic and plays a significant r...

Full description

Bibliographic Details
Main Authors: E. G. B. Vijverberg, T. M. Axelsen, A. R. Bihlet, K. Henriksen, F. Weber, K. Fuchs, J. E. Harrison, K. Kühn-Wache, P. Alexandersen, N. D. Prins, Philip Scheltens
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer
Clinical trials; Small molecules; Puroglutamate
Abeta
Placebo
Amyloid
Online Access:https://doi.org/10.1186/s13195-021-00882-9

Internet

https://doi.org/10.1186/s13195-021-00882-9

Similar Items